Coya Therapeutics shares are trading higher after the company announced a publication demonstrating that COYA 302 increased three biomarkers in ALS patients compared to controls.

Benzinga Newsdesk www.benzinga.com Positive 95.8%

Neg 0% Neu 0% Pos 95.8%

Comments

No comments yet. Be the first!